M Smith, A Dai, G Ghilardi, KV Amelsberg,
SM Devlin… - Nature medicine, 2022 - nature.com
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …